The health insurer posts strong revenue and earnings growth as it awaits approval to acquire WellCare Health Plans.
Seven steps to help you invest more effectively in the war on cancer.
The laboratory services company beat Wall Street estimates despite reporting only modest revenue growth and another earnings decline.
The biotech stock is enjoying a second day of big gains after the company reported promising results for experimental drug ACH-5228.
Great results from an early-stage clinical study provided a big boost to this small biotech.
The cannabis-focused e-commerce technology provider didn't return to growth in the quarter, but there were hints that its top and bottom lines are stabilizing.
The online pet pharmacy posts declining sales and earnings in the face of stiff competition.
Here are seven simple steps to follow when considering investing in the fast-growing medical device industry.
Worrisome information from a major opioid case appears to be weighing on the drug stock.
The pros and the cons for this giant healthcare stock.
These stocks should be safer than most when the next major market downturn comes.
Which stock wins in a head-to-head matchup between a top U.S. supplier to the cannabis industry and an up-and-coming Canadian cannabis producer?
Here are AbbVie's grades on its previous acquisition deals. And they look ugly overall.
Which stock wins in a head-to-head matchup between these two big drugmakers?
Thinking about selling your Canopy Growth stock? Don't do it over these three reasons.
Their competitive advantages and long-term growth prospects make these three stocks keepers.
One top analyst isn't as bullish about this top pot stock as he was just three months ago. And it makes no sense.
Dilution is on the way, causing at least temporary pain for shareholders.
Another bump in the road for Acthar is weighing on the drugmaker.
Here's what Gilead's getting with its $5.1 billion Galapagos collaboration.